Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
alny · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Alnylam Pharmaceuticals, Inc. (ALNY) measures how much investors pay for each dollar of the company's trailing earnings. ALNY's current PE ratio of 67.14x is calculated by dividing its stock price of $289.25 by its TTM earnings per share of $4.34. −59.6% discount vs 5Y avg 166.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Alnylam Pharmaceuticals, Inc.You ALNY | $38.6B | 67.14x | +113.5% | $4.34 |
 argenx SE ARGX | $54.5B | 39.90x | +26.9% | $21.08 |
 Becton, Dickinson and Company BDX | $54.3B | 25.13x | -20.1% | $5.85 |
 Cardinal Health, Inc. CAH | $48.2B | 25.94x | -17.5% | $6.48 |
 Cigna Corporation CI | $76.4B | 12.29x | -60.9% | $22.40 |
 Cencora, Inc. COR | $53.5B | 38.98x | +23.9% | $8.02 |
 Edwards Lifesciences Corporation EW | $49.2B | 46.44x | +47.7% | $1.84 |
Industry Average 6 peers with valid PE | — | 31.45x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 166.04x | $2.39 | — | |
2024-12-31 FY2024 | — | $-2.18 | — | |
2023-12-31 FY2023 | — | $-3.52 | — | |
2022-12-31 FY2022 | — | $-9.30 | — | |
2021-12-31 FY2021 | — | $-7.20 | — | |
2020-12-31 FY2020 | — | $-7.46 | — | |
2019-12-31 FY2019 | — | $-8.11 | — | |
2018-12-31 FY2018 | — | $-7.57 | — | |
2017-12-31 FY2017 | — | $-5.42 | — | |
2016-12-31 FY2016 | — | $-4.79 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Alnylam Pharmaceuticals, Inc. (ALNY) measures how much investors pay for each dollar of the company's trailing earnings. ALNY's current PE ratio of 67.14x is calculated by dividing its stock price of $289.25 by its TTM earnings per share of $4.34.
Frequently asked questions
ALNY pe ratio · 6 questionsALNY's current PE ratio is 67.14x as of 2026-06-08, based on a stock price of $289.25 and TTM EPS of $4.34. Data sourced from Financial Modeling Prep via ALNY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Alnylam Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08